HK1113308A1 - Pharmaceutical formulations of gallium salts - Google Patents

Pharmaceutical formulations of gallium salts

Info

Publication number
HK1113308A1
HK1113308A1 HK08102777.7A HK08102777A HK1113308A1 HK 1113308 A1 HK1113308 A1 HK 1113308A1 HK 08102777 A HK08102777 A HK 08102777A HK 1113308 A1 HK1113308 A1 HK 1113308A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical formulations
gallium salts
gallium
salts
formulations
Prior art date
Application number
HK08102777.7A
Other languages
English (en)
Chinese (zh)
Inventor
Lewis Bender
Bavani Shankar
Catherina Oshaughnessy
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Publication of HK1113308A1 publication Critical patent/HK1113308A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK08102777.7A 2004-12-29 2008-03-10 Pharmaceutical formulations of gallium salts HK1113308A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64073904P 2004-12-29 2004-12-29
US67753305P 2005-05-03 2005-05-03
PCT/US2005/047603 WO2006072070A2 (en) 2004-12-29 2005-12-29 Pharmaceutical formulations of gallium salts

Publications (1)

Publication Number Publication Date
HK1113308A1 true HK1113308A1 (en) 2008-10-03

Family

ID=36615571

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08102777.7A HK1113308A1 (en) 2004-12-29 2008-03-10 Pharmaceutical formulations of gallium salts

Country Status (11)

Country Link
US (1) US9345725B2 (de)
EP (1) EP1830831B1 (de)
JP (1) JP4907552B2 (de)
AU (1) AU2005321803B2 (de)
BR (1) BRPI0517574A (de)
CA (1) CA2591515C (de)
ES (1) ES2535311T3 (de)
HK (1) HK1113308A1 (de)
MX (1) MX2007008082A (de)
NZ (1) NZ556373A (de)
WO (1) WO2006072070A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1453816B1 (de) 2001-11-13 2013-09-18 Emisphere Technologies, Inc. Phenoxyaminverbindungen und zusammensetzungen zur verabreichung von wirkstoffen
CA2626029A1 (en) 2005-11-04 2007-05-18 Genta Incorporated Pharmaceutical gallium compositions and methods
WO2008003050A2 (en) 2006-06-28 2008-01-03 Emisphere Technologies, Inc. Gallium nitrate formulations
EP2099464B1 (de) * 2006-11-09 2016-05-25 BERNSTEIN, Lawrence Richard Lokale verabreichung von galliumzusammensetzungen zur schmerzbehandlung
WO2009111681A2 (en) * 2008-03-07 2009-09-11 Lawrence Bernstein Gallium compounds and methods of use to treat inflammatory bowel disease
CN102665421A (zh) 2009-03-30 2012-09-12 尼基制药公司 治疗骨质疏松的方法
US20110318265A1 (en) * 2009-04-07 2011-12-29 Bernstein Lawrence R Coupled identification and treatment of cancer
WO2011017346A2 (en) * 2009-08-03 2011-02-10 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
US9072783B2 (en) * 2009-11-18 2015-07-07 Aridis Pharmaceuticals Highly dispersible powders, compositions and methods for preparation
WO2014031874A1 (en) * 2012-08-23 2014-02-27 Emisphere Technologies, Inc. Phenoxy alkyl diethanolamine and diisopropanolamine compounds for delivering active agents
ES2813340T3 (es) * 2012-09-21 2021-03-23 Intensity Therapeutics Inc Método de tratamiento del cáncer

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1219210A (en) 1982-10-22 1987-03-17 Warrell Raymond P., Jr. Use of gallium salts to treat disorders of calcium homeostasis
US4704277A (en) 1985-04-30 1987-11-03 Sloan-Kettering Institute For Cancer Research Methods of treating bone disorders
US5258376A (en) 1989-11-22 1993-11-02 Bernstein Lawrence R Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones
US6004951A (en) 1989-11-22 1999-12-21 Bernstein; Lawrence Richard Administration of gallium complexes of 3-hydroxy-4-pyrones to provide physiologically active gallium levels in a mammalian individual
US5574027A (en) 1989-11-22 1996-11-12 Bernstein; Lawrence R. Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones
US5686116A (en) 1990-01-12 1997-11-11 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Methods of enhancing repair, healing and augmentation of bone implants
US5556645A (en) 1990-01-12 1996-09-17 Bockman; Richard Methods of enhancing wound healing and tissue repair
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5693338A (en) 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US6099856A (en) 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
US5578323A (en) 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US5443841A (en) 1992-06-15 1995-08-22 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US5541155A (en) 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US5451410A (en) 1993-04-22 1995-09-19 Emisphere Technologies, Inc. Modified amino acids for encapsulating active agents
US5629020A (en) 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5447728A (en) 1992-06-15 1995-09-05 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US5196412A (en) 1991-03-06 1993-03-23 Johnson Matthey, Inc. Gallium compounds
DE69225484T2 (de) 1991-07-25 1998-12-10 Philippe Reims Collery Gallium iii komplexe, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5811127A (en) 1992-06-15 1998-09-22 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US6916489B2 (en) 1992-06-15 2005-07-12 Emisphere Technologies, Inc. Active agent transport systems
US5401516A (en) 1992-12-21 1995-03-28 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
US5958457A (en) 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US6610329B2 (en) 1993-04-22 2003-08-26 Emisphere Technologies Inc. Compositions for the delivery of antigens
US20040062773A1 (en) 1993-04-22 2004-04-01 Emisphere Technologies Inc. Compositions for the delivery of antigens
DE69434418T2 (de) 1993-04-22 2005-12-22 Emisphere Technologies, Inc. Orale Dareichungsform
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US20010003001A1 (en) 1993-04-22 2001-06-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO1995024203A1 (en) 1994-03-11 1995-09-14 Von Hoff Daniel D Improvement in treatment of aids-associated non-hodgkin's lymphoma by gallium nitrate
BR9604880A (pt) 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5965121A (en) 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5989539A (en) 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6090958A (en) 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5820881A (en) 1995-04-28 1998-10-13 Emisphere Technologies, Inc. Microspheres of diamide-dicarboxylic acids
US5824345A (en) 1995-06-07 1998-10-20 Emisphere Technologies, Inc. Fragrances and flavorants
US5667806A (en) 1995-06-07 1997-09-16 Emisphere Technologies, Inc. Spray drying method and apparatus
US6051258A (en) 1995-06-07 2000-04-18 Emisphere Technologies, Inc. Proteinoid emulsions and methods for preparation and use thereof
US5750147A (en) 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
GB2320248B (en) 1995-09-11 1999-04-14 Emisphere Tech Inc Method for preparing omega-aminoalkanoic acid derivatives from cycloalkanones
EP0883629A1 (de) 1996-02-29 1998-12-16 Emisphere Technologies, Inc. Oligopeptide zur Arzneimittelgabe
IL126318A (en) * 1996-03-29 2004-09-27 Emisphere Tech Inc Compounds and compositions for delivering active agents and some novel carrier compounds
CA2258264A1 (en) 1996-06-14 1997-12-18 Emisphere Technologies, Inc. Microencapsulated fragrances and method for preparation
US5958451A (en) 1996-09-03 1999-09-28 Yung Shin Pharm Ind. Co., Ltd. Process for producing porous, controlled-release capsules and encapsulated composition
CA2243643A1 (en) 1996-11-18 1998-05-28 Susan Haas Methods and compositions for inducing oral tolerance in mammals
US5776888A (en) 1997-02-07 1998-07-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5879681A (en) * 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US5876710A (en) 1997-02-07 1999-03-02 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
US5990166A (en) 1997-02-07 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2279331C (en) 1997-02-07 2010-04-20 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6358504B1 (en) 1997-02-07 2002-03-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6060513A (en) 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6051561A (en) 1997-02-07 2000-04-18 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
US5804688A (en) * 1997-02-07 1998-09-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5939381A (en) 1997-02-07 1999-08-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6313088B1 (en) 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US5863944A (en) 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5962710A (en) 1997-05-09 1999-10-05 Emisphere Technologies, Inc. Method of preparing salicyloylamino acids
US6440929B1 (en) 1998-07-27 2002-08-27 Emisphere Technologies, Inc. Pulmonary delivery of active agents
AU745290B2 (en) 1998-07-27 2002-03-21 Emisphere Technologies, Inc. Pulmonary delivery of active agents
TR200100366T2 (tr) 1998-08-07 2001-11-21 Emisphere Technologies, Inc. Aktif madde dağıtmaya mahsus bileşikler ve bileşimler.
US6991798B1 (en) * 1998-08-07 2006-01-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP2002534363A (ja) 1999-01-08 2002-10-15 エミスフェアー・テクノロジーズ・インク ポリマー性デリバリー剤及びデリバリー剤化合物
DE19904562C2 (de) 1999-02-04 2002-06-13 Forschungszentrum Juelich Gmbh Geschwindigkeitsselektor zur Monochromatisierung eines Neutronenstrahls
EP1149066B1 (de) 1999-02-05 2005-11-09 Emisphere Technologies, Inc. Verfahren zur herstellung alkylierter salicylamide
ES2251976T3 (es) 1999-02-11 2006-05-16 Emisphere Technologies, Inc. Compuestos y composiciones de oxadiazol para aportar agentes activos.
AU3240900A (en) 1999-02-22 2000-09-04 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
CA2364849A1 (en) 1999-02-26 2000-08-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO2000059480A1 (en) 1999-04-05 2000-10-12 Emisphere Technologies, Inc. Lyophilized solid dosage forms and methods of making
IL145546A0 (en) * 1999-04-05 2002-06-30 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
IL149336A0 (en) 1999-11-05 2002-11-10 Emisphere Tech Inc Phenyl amine carboxylic acid compounds and compositions for delivering active agents
AU1594801A (en) 1999-11-12 2001-06-06 Emisphere Technologies, Inc. Liquid heparin formulation
AU2274201A (en) 1999-12-16 2001-06-25 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP4879433B2 (ja) 2000-01-13 2012-02-22 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための化合物および組成物
US6693898B1 (en) 2000-02-01 2004-02-17 Lucent Technologies, Inc. Call control model for a packet-based intelligent telecommunications network
US6384278B1 (en) 2000-02-04 2002-05-07 Emisphere Technologies, Inc. Boron-mediated amidation of carboxylic acids
CA2402719C (en) 2000-03-21 2012-03-20 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides via a dicarboxylate intermediate
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
NZ523017A (en) * 2000-06-29 2004-10-29 Emisphere Tech Inc Compounds and compositions for delivering active agents and preparation method thereof
US7227033B2 (en) * 2002-01-09 2007-06-05 Emisphere Technologies, Inc. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate
WO2002016309A1 (en) 2000-08-18 2002-02-28 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU2001288277A1 (en) 2000-08-18 2002-03-04 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO2002020466A1 (en) 2000-09-06 2002-03-14 Emisphere Technologies, Inc. Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
ATE396967T1 (de) 2000-09-06 2008-06-15 Emisphere Tech Inc (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
MXPA03007837A (es) 2001-03-01 2004-03-16 Emisphere Techonologies Inc Composiciones para suministrar bisfosfonatos.
CN1494420A (zh) 2001-03-01 2004-05-05 埃米斯菲尔技术公司 释放活性成分的化合物和组合物
US20030225300A1 (en) 2001-04-19 2003-12-04 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
AU2002316200A1 (en) 2001-06-08 2002-12-23 Emisphere Technologies, Inc. Compound and composition for delivering active agents
JP2005528322A (ja) 2001-09-26 2005-09-22 エミスフェアー・テクノロジーズ・インク ジカルボキシラート中間体を経てフェノキシアルカン酸、アルケン酸およびアルキン酸ならびにそれらの塩を調製する方法
EP1453816B1 (de) 2001-11-13 2013-09-18 Emisphere Technologies, Inc. Phenoxyaminverbindungen und zusammensetzungen zur verabreichung von wirkstoffen
EP1461031B1 (de) * 2001-11-29 2016-06-29 Emisphere Technologies, Inc. Formulierungen zur oralen verabreichung von cromolyn-natrium
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
IL150894A0 (en) 2002-07-24 2003-04-10 A method for measuring road traffic load based on analyzing cellular communications
CA2511530C (en) 2003-01-06 2013-07-09 Emisphere Technologies, Inc. Night-time oral insulin therapy
AU2004220544B2 (en) 2003-03-06 2010-06-17 Emisphere Technologies, Inc. Oral insulin therapies and protocol
WO2005115406A2 (en) * 2004-04-16 2005-12-08 Emisphere Technologies, Inc. 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
CA2626029A1 (en) * 2005-11-04 2007-05-18 Genta Incorporated Pharmaceutical gallium compositions and methods

Also Published As

Publication number Publication date
EP1830831A4 (de) 2010-12-15
WO2006072070A2 (en) 2006-07-06
EP1830831B1 (de) 2015-01-21
BRPI0517574A (pt) 2008-10-14
US9345725B2 (en) 2016-05-24
JP4907552B2 (ja) 2012-03-28
US20090123562A1 (en) 2009-05-14
CA2591515A1 (en) 2006-07-06
MX2007008082A (es) 2007-09-05
JP2008526772A (ja) 2008-07-24
EP1830831A2 (de) 2007-09-12
CA2591515C (en) 2010-06-22
ES2535311T3 (es) 2015-05-08
AU2005321803A1 (en) 2006-07-06
NZ556373A (en) 2010-01-29
WO2006072070A3 (en) 2007-12-06
AU2005321803B2 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
HK1113308A1 (en) Pharmaceutical formulations of gallium salts
EP1729744A4 (de) Pharmazeutische formulierungen
ZA200900345B (en) Preparation of pharmaceutical formulations
GB0426301D0 (en) Pharmaceutical formulations
EP1933862A4 (de) Verfahren und zusammensetzungen zur oralen verabreichung von proteinen
EP1796632A4 (de) Organogel-formulierungen für therapeutische anwendungen
IL180691A0 (en) Organo-gel formulations for therapeutic applications
EP1765283A4 (de) Pharmazeutische zusammensetzungen
ZA200701557B (en) Pharmaceutical compositions comprising diclofenac
EP1757273A4 (de) Präparat zur oralen verabreichung
IL180031A0 (en) Stable pharmaceutical formulations of benzimidazole compounds
IL181827A0 (en) Donepezil salts suitable for the preparation of pharmaceutical compositions
EP1895991A4 (de) Formulierungen mit modifizierter freisetzung von arzneimitteln gegen erregbarkeit
IL177402A0 (en) Composition for oral administration of tamsulosin hydrochloride
EP2001400A4 (de) Orale formulierungen von glycyl-2-methylprolyl-glutamat
IL183986A0 (en) Pharmaceutical compounds and compositions
EP1753405A4 (de) Pharmazeutische formulierung mit kontrollierter freisetzung
EP1805154A4 (de) Pharmazeutische zusammensetzungen
IL183930A0 (en) Use of cladribine for preparation of pharmaceutical compositions
EP1755568A4 (de) Formulierung mit kontrollierter freisetzung zur oralen verabreichung von metformin
EP1767531A4 (de) 6-hydroxybenzbromaron oder salze davon enthaltende medizinische zusammensetzungen
EP1750767A4 (de) Pharmazeutische formulierungen zur hemmung der säuresekretion und herstellungs- und anwendungsverfahren
EP1740541A4 (de) Therapeutische formulierungen von desoxyepothilonen
GB0423800D0 (en) New pharmaceutical formulations
HK1105358A1 (en) Solid pharmaceutical formulation

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190101